Annual Statement of Changes in Beneficial Ownership (5)

Share Name	Share Symbol	Market	Type
Cellular Biomedicine Group Inc	NASDAQ:CBMG	NASDAQ	Common Stock

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.00%	19.74	19.74	19.80				0	01:00:00

Annual Statement of Changes in Beneficial Ownership (5)

13/02/2020 10:22pm

Edgar (US Regulatory)

FORM 5

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
[ ] Form 3 Holdings Reported
[X] Form 4 Transactions Reported UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0362
Estimated average burden
hours per response... 1.0
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* Liu Tony	2. Issuer Name and Ticker or Trading Symbol Cellular Biomedicine Group, Inc. [CBMG]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) CEO, CFO
(Last) (First) (Middle) 1345 AVENUE OF THE AMERICAS, FL. 15	3. Statement for Issuer's Fiscal Year Ended (MM/DD/YYYY) 12/31/2019
(Street) NEW YORK, NY 10105 (City) (State) (Zip)	4. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form Filed by One Reporting Person ___ Form Filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock ⁽¹⁾	1/25/2019		S4	875	D	$17.69 ⁽²⁾	255392 ⁽¹²⁾	D
Common Stock	2/27/2019		S4	875	D	$18.06 ⁽³⁾	254517 ⁽¹²⁾	D
Common Stock	3/27/2019		S4	875	D	$16.80 ⁽⁴⁾	253642 ⁽¹²⁾	D
Common Stock	4/29/2019		S4	875	D	$16.89 ⁽⁵⁾	252767 ⁽¹²⁾	D
Common Stock	5/28/2019		S4	875	D	$16.94 ⁽⁶⁾	251892 ⁽¹²⁾	D
Common Stock	6/27/2019		S4	875	D	$14.94 ⁽⁷⁾	251017 ⁽¹²⁾	D
Common Stock	7/29/2019		S4	875	D	$13.70 ⁽⁸⁾	250142 ⁽¹²⁾	D
Common Stock	8/27/2019		S4	875	D	$11.47 ⁽⁹⁾	249267 ⁽¹²⁾	D
Common Stock	9/27/2019		S4	875	D	$14.68 ⁽¹⁰⁾	248392 ⁽¹²⁾	D
Common Stock	10/28/2019		S4	875	D	$15.08 ⁽¹¹⁾	247517 ⁽¹²⁾	D

*Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (MM/DD/YYYY)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned at End of Issuer's Fiscal Year (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (Right to Buy) ⁽¹³⁾	$35.53	4/6/2015		A4	30000		⁽¹⁵⁾	4/6/2025	Common Stock	30000	$0	30000	D
Employee Stock Option (Right to Buy) ⁽¹³⁾	$40.00	1/23/2016		A4	13000		⁽¹⁶⁾	1/23/2026	Common Stock	13000	$0	13000	D
Employee Stock Option (Right to Buy) ⁽¹³⁾	$20.00	4/11/2016		A4	40000		⁽¹⁷⁾	4/11/2026	Common Stock	40000	$0	40000	D
Employee Stock Option (Right to Buy) ⁽¹³⁾	$40	5/14/2017		J4 ⁽¹⁴⁾		13000	⁽¹⁶⁾	1/23/2026	Common Stock	13000	$0	0	D
Employee Stock Option (Right to Buy) ⁽¹³⁾	$7.23						⁽¹⁸⁾	3/5/2023	Common Stock	5300		5300 ⁽²⁴⁾	D
Employee Stock Option (Right to Buy) ⁽¹³⁾	$5.00						⁽¹⁹⁾	1/3/2024	Common Stock	255000		255000 ⁽²⁵⁾	D
Employee Stock Option (Right to Buy) ⁽¹³⁾	$20.63						⁽²⁰⁾	7/23/2021	Common Stock	15000		15000 ⁽²⁶⁾	D
Employee Stock Option (Right to Buy) ⁽¹³⁾	$20.63						⁽²¹⁾	8/14/2021	Common Stock	15000		15000 ⁽²⁶⁾	D
Employee Stock Option (Right to Buy) ⁽¹³⁾	$15.53						⁽²²⁾	12/31/2021	Common Stock	105800		105800 ⁽²⁶⁾	D
Employee Stock Option (Right to Buy) ⁽¹³⁾	$12.55						1/21/2017	1/21/2027	Common Stock	30000		30000 ⁽²⁷⁾	D
Employee Stock Option (Right to Buy) ⁽¹³⁾	$12.40						⁽²³⁾	3/3/2027	Common Stock	120000		120000 ⁽²⁷⁾	D

Explanation of Responses:
(1)	As previously reported on the Reporting Person's Form 4 filed on April 3, 2017, on March 27, 2017, the Reporting Person was granted 120,000 restricted stock units ("RSUs") (Grant No. LTIP RSU G1) under the Cellular Biomedicine Group, Inc. 2014 Stock Incentive Plan (the "Plan"), which RSUs vest according to the following schedule: 1/48th per month, with the first installment vested on March 27, 2017.
(2)	On January 25, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $17.69. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
(3)	On February 27, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $18.06. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
(4)	On March 27, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $16.80. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
(5)	On April 29, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $16.89. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
(6)	On May 28, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $16.94. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
(7)	On June 27, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $14.94. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
(8)	On July 29, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $13.70. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
(9)	On August 27, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $11.47. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
(10)	On September 27, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $14.68. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
(11)	On October 28, 2019, upon vesting of his RSUs, the Reporting Person sold an aggregate of 875 shares of common stock at a per share price of $15.08. The transaction was effectuated for the purpose of fulfilling his tax obligations in accordance with the terms of his employment agreement and the Plan. Accordingly, the Reporting Person had no discretion with regard to the timing of the transaction.
(12)	Due to administrative errors, the Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year was inaccurately reported in Column 5 of Table I of the Reporting Person's Form 5 filed on February 14, 2019 (the "2019 Form 5") and prior Section 16 reports. As a result, the Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year in Column 5 of Table I of this form does not correspond with the number reported in the 2019 Form 5. This form corrects the prior reporting and rounding errors made in Column 5 of Table I of the Reporting Person's prior Section 16 reports.
(13)	In the Reporting Person's prior Section 16 reports, employee stock options were referred to using various differing titles. For convenience, in the Reporting Person's future Section 16 reports, all employee stock options to buy common stock will be referred to using the title "Employee Stock Option (Right to Buy)." The nature and economic terms of the re titled employee stock options remain unchanged.
(14)	These derivatives securities were cancelled on May 14, 2017 and the Reporting Person received no value in connection with this cancellation.
(15)	As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on July 29, 2016, on April 6, 2015, the Reporting Person was granted an employee stock option to purchase up to 30,000 shares of common stock, of which 9,000 shares vested and became fully exercisable on April 6, 2016; 9,000 shares vested and became fully exercisable on April 6, 2017; and 12,000 shares vested and became fully exercisable on April 6, 2018.
(16)	As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on March 17, 2017, on January 23, 2016, the Reporting Person was granted an employee stock option to purchase up to 13,000 shares of common stock, of which 3,900 shares vested and became fully exercisable on January 23, 2017; 3,900 shares vested and became fully exercisable on January 23, 2018; and 5,200 shares vested and became fully exercisable on January 23, 2019.
(17)	As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on March 17, 2017, on April 11, 2016, the Reporting Person was granted an employee stock option to purchase up to 40,000 shares of common stock, of which 12,000 shares vested and became fully exercisable on April 11, 2017; 12,000 shares vested and became fully exercisable on April 11, 2018; and 16,000 shares vested and became fully exercisable on April 11, 2019.
(18)	This option vested over a period of three years according to the following schedule: 1/36th per month following the vesting commencement date of March 5, 2013.
(19)	This option vested over a period of three years according to the following schedule: 1/36th per month following the vesting commencement date of January 3, 2014.
(20)	This option vested over a period of three years according to the following schedule: 1/3 on July 23, 2015 and 1/3 on each anniversary thereafter.
(21)	This option vested over a period of three years according to the following schedule: 1/3 on August 14, 2015 and 1/3 on each anniversary thereafter.
(22)	This option vested over a period of three years according to the following schedule: 1/3 on December 31, 2015 and 1/3 on each anniversary thereafter.
(23)	This option (Grant No. 14-324) vests over a period of four years according to the following schedule: 1/48th per month, with the first installment vested on March 27, 2017.
(24)	The acquisition of these derivative securities was previously reported on the Reporting Person's Form 5 filed on February 27, 2014. This holdings entry is included solely to reconfirm the number derivative securities of this class beneficially owned by the Reporting Person.
(25)	The acquisition of these derivative securities was previously reported on the Reporting Person's Form 5 filed on February 13, 2015. As a result of an administrative error, the number of derivative securities of this class beneficially owned by the Reporting Person following the reported transaction was inaccurately reported in Column 9 of Table II. This holdings entry is included to correct the number derivative securities of this class beneficially owned by the Reporting Person.
(26)	The acquisition of these derivative securities was previously reported on the Reporting Person's Form 5 filed on February 17, 2015. As a result of an administrative error, the number of derivative securities of this class beneficially owned by the Reporting Person following the reported transaction was inaccurately reported in Column 9 of Table II. This holdings entry is included to correct the number derivative securities of this class beneficially owned by the Reporting Person.
(27)	The acquisition of these derivative securities was previously reported on the Reporting Person's Form 4 filed on April 3, 2017. This holdings entry is included solely to reconfirm the number derivative securities of this class beneficially owned by the Reporting Person.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Liu Tony 1345 AVENUE OF THE AMERICAS, FL. 15 NEW YORK, NY 10105	X		CEO, CFO

Signatures
/s/Bizuo (Tony) Liu		2/11/2020
^**Signature of Reporting Person		Date

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

CBMG Cellular Biomedicine Group Inc

Annual Statement of Changes in Beneficial Ownership (5)

13/02/2020 10:22pm

Edgar (US Regulatory)

1 Year Cellular Biomedicine Chart

1 Month Cellular Biomedicine Chart

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Cellular Biomedicine Group Inc (CBMG) News

CBMG Cellular Biomedicine Group Inc

Annual Statement of Changes in Beneficial Ownership (5)

13/02/2020 10:22pm

Edgar (US Regulatory)

1 Year Cellular Biomedicine Chart

1 Month Cellular Biomedicine Chart

Your Recent History

Company

Business

Popular

Get The App